Skip to main content

Table 2 The status of FGFR1 gene amplification and protein overexpression in patients with hypopharyngeal and laryngeal squamous cell carcinoma

From: Prognostic implications of Fibroblast growth factor receptor 1 (FGFR1) gene amplification and protein overexpression in hypopharyngeal and laryngeal squamous cell carcinoma

CharacteristicsFGFR1 amplification, n = 66P valueFGFR1 high expression, n = 199P value
Present, n (%)Absent, n (%)Present, n (%)Absent, n (%)
Total8 (12.1)58 (87.9) 21 (10.6)178 (89.4) 
Primary sites  0.015  0.307
 Hypopharynx6 (75.0)36 (62.1) 6 (28.6)47 (26.4) 
 Larynx2 (25.0)22 (37.9) 15 (71.4)131 (73.6) 
Gender  0.771  0.145
 Female0 (0.0)2 (3.4) 3 (14.3)10 (5.6) 
 Male8 (100.0)56 (96.6) 18 (85.7)168 (94.4) 
Age (years)  0.452  0.820
 Median (range)68.0 (55–73)63.0 (42–88) 63.0 (45–78)64.0 (30–88) 
 < 653 (37.5)33 (56.9) 12 (57.1)95 (53.4) 
 ≥ 655 (62.5)25 (43.1) 9 (42.9)83 (46.6) 
Smoking  0.405  0.302
 Never smoker2 (25.0)7 (12.1) 3 (14.3)19 (10.7) 
 Former smoker1 (12.5)15 (25.9) 6 (28.6)45 (25.3) 
 Current smoker5 (62.5)36 (62.1) 12 (57.1)114 (64.0) 
Alcohol  0.196  0.778
 Non- or social- drinker0 (0.0)13 (22.4) 5 (23.8)37 (20.8) 
 Heavy drinker8 (100.0)45 (77.6) 16 (76.2)141 (79.2) 
p16 status  0.551  0.697
 Negative7 (87.5)47 (81.0) 14 (82.4)131 (88.5) 
 Positive1 (12.5)11 (19.0) 3 (17.6)17 (11.5) 
 Unknown     
Histologic differentiation  0.355  <  0.001
 Well differentiated2 (25.0)15 (25.9) 1 (4.8)58 (32.6) 
 Moderately differentiated4 (50.0)37 (63.8) 11 (52.4)108 (60.7) 
 Poorly differentiated2 (25.0)6 (10.3) 9 (42.9)12 (6.7) 
Lymphovascular invasion  0.031  0.096
 Absent4 (50.0)50 (86.2) 13 (61.9)141 (79.2) 
 Present4 (50.0)8 (13.8) 8 (38.1)37 (20.8) 
Perineural invasion  0.614  0.335
 Absent7 (87.5)52 (89.7) 16 (76.2)152 (85.4) 
 Present1 (12.5)6 (10.3) 5 (23.8)26 (14.6) 
Positive resection margin  0.537  0.494
 Absent4 (50.0)32 (55.2) 16 (76.2)130 (73.0) 
 Present4 (50.0)26 (44.8) 5 (23.8)48 (27.0) 
Pathological T-classification  0.365  0.238
 pT13 (37.5)29 (50.0) 4 (19.0)59 (33.1) 
 pT24 (50.0)18 (31.0) 9 (42.9)49 (27.5) 
 pT30 (0.0)10 (17.2) 4 (19.0)48 (27.0) 
 pT4a1 (9.1)1 (1.7) 4 (19.0)22 (12.4) 
Pathological N-classification  0.012  0.003
 pN03 (27.3)32 (58.2) 6 (28.6)105 (59.0) 
 pN10 (0.0)4 (7.3) 1 (4.8)12 (6.7) 
 pN21 (9.1)7 (12.7) 4 (19.0)22 (12.4) 
 pN37 (63.6)12 (21.8) 10 (47.6)39 (21.9) 
Pathological stage  0.047  0.001
 Stage I2 (25.0)24 (41.4) 1 (4.8)53 (29.8) 
 Stage II0 (0.0)5 (8.6) 3 (14.3)26 (14.6) 
 Stage III0 (0.0)7 (12.1) 2 (9.5)30 (16.9) 
 Stage IVA1 (12.5)8 (13.8) 5 (23.8)30 (16.9) 
 Stage IVB5 (62.5)14 (24.1) 10 (47.6)39 (21.9) 
Recurrence  0.042  0.263
 No4 (50.0)49 (84.5) 14 (66.7)141 (79.2) 
 Yes4 (50.0)9 (15.5) 7 (33.3)37 (20.8) 
 Local recurrence only2 (50.0)5 (55.6) 2 (28.6)20 (54.1) 
 Distant recurrence2 (50.0)4 (44.4) 5 (71.4)17 (45.9)